Cantor Fitzgerald raised the firm’s price target on Soleno Therapeutics (SLNO) to $123 from $67 and keeps an Overweight rating on the shares. Soleno Therapeutics announced Food and Drug Administration approval of VYKAT XR for the treatment of hyperphagia in patients over 4 years old with Prader-Willi Syndrome, and the full label was in-line with expectations, reflecting a best-case scenario, the analyst tells investors in a research note. The firm sees shares up “meaningfully” on the news.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics price target raised to $102 from $72 at Baird
- Aardvark Therapeutics price target raised to $26 from $22 at BofA
- Soleno Stock (SLNO) Soars 32% after FDA Greenlights New Drug
- Closing Bell Movers: Stock futures, Big Three automakers fall on auto tariffs
- Soleno Therapeutics announces FDA approval of VYKAT XR to treat hyperphagia